Dr Peter Voorhees reviews bispecifics under development and updated outcomes data from the MonumenTAL-1 trial, evaluating talquetamab in patients with R/R multiple myeloma.
Videos
Peter Voorhees, MD, presents a case of a 63-year-old man with R/R multiple myeloma, shares his initial impressions, and discusses the assessment of clinical relapse in patients with R/R multiple myeloma.
Matthew Ingham, MD, discusses some of the most recent clinical updates in the sarcoma space.
Nathan Pennell, MD, PhD, discusses the importance of developing drugs based on resistance to previous treatments in patients with non–small cell lung cancer.
Thomas Flaig, MD, discusses some of the updated and current NCCN guidelines for patients with bladder cancer.
Cyrus M. Khan, MD, discusses the mechanism of action of glofitamab and its potential use as a treatment option for patients with relapsed/refractory large B-cell lymphoma.
Dr Matthew Galsky contemplates how he would use immunotherapy in patients with MIBC, if it were available for use in both the neoadjuvant and adjuvant setting.
Matthew Galsky, MD, highlights some remaining unmet needs for patients with MIBC, and currently ongoing clinical trials in the neoadjuvant MIBC treatment setting that excite him.
Dr Matthew Galsky explains the adjuvant therapy regimen he would have recommended for the patient with MIBC from the presented case, and whether patient preference factors into his decisions in clinical practice.
Matthew Galsky, MD, explains safety and efficacy data from the CheckMate 274 trial, which led to the FDA approval of adjuvant nivolumab for patients with MIBC, and highlights important data updates from recent conferences.
Dr Matthew Galsky reviews the available adjuvant therapy options for patients with stage II or III MIBC who previously underwent bladder removal surgery.
Matthew Galsky, MD, presents the case of a 55-year-old man with stage T2N0M0 muscle-invasive bladder cancer (MIBC) for review, and explains how cisplatin eligibility is defined in patients.
Stephen Oh, MD, PhD, explains the different types of myelofibrosis and describes the signs and symptoms.
Rachel Würstlein, MD, discusses the use of trastuzumab emtansine following the KAMILLA trial which evaluated the agent in patients with HER2-positive locally advanced or metastatic breast cancer who have brain metastases.
Susana Banerjee, MBBS, PhD, discusses the significance of the long-term results of the MEDIOLA trial of patients with ovarian cancer.
The panel closes by summarizing recent advances in the field and shares hopes for future improvements in molecular testing and treatment options for patients with mNSCLC.
A focused discussion on whether immunotherapy might be an effective treatment option for patients with RET-positive mNSCLC.
The panel reviews LIBRETTO-001 and ARROW safety data on selpercatinib and pralsetinib in RET fusion-positive mNSCLC, and share their clinical experience in adverse event (AE) management in patients who are receiving one of these therapies.
Dr Piotrowska outlines the RET tyrosine kinase inhibitors (TKIs) selpercatinib and pralsetinib, which are available for patients with RET fusion-positive mNSCLC, then Dr Neal follows with a discussion of supporting efficacy data from the LIBRETTO-001 and ARROW trials.
Joel Neal, MD, presents a second case of a 67-year-old man with no smoking history who was diagnosed with RET-rearranged mNSCLC, while Michelle Shiller, DO, AP/CP, MGP, touches on molecular testing approaches in patients who are suspected of having a RET alteration.
Zosia Piotrowska, MD, explains how she might treat a patient with EGFR exon 20-mutated mNSCLC who develops an EGFR T790M mutation after mobocertinib treatment.
Laura A. Dawson, MD, FRCPC, discusses findings from the NRG/RTOG 1112 study of stereotactic body radiation therapy followed by sorafenib vs sorafenib alone in hepatocellular carcinoma.
Karen L. Reckamp, MD, MS, discusses findings from the phase 2 Lung-MAP substudy S1800A of pembrolizumab and ramucirumab in patients with stage IV, previously-treated non–small cell lung cancer.
Gayathri Ravi, MD, discusses the role of minimal residual disease testing in patients with newly diagnosed multiple myeloma.
Robert Holloway, MD, highlights the issue of racial disparity in endometrial cancer, and the critical unmet needs for patients.
Insights into the goals of second-line therapy for patients with advanced/recurrent endometrial carcinoma, and best strategies for adverse event management.
Dr Robert Holloway explains what second-line treatment regimen he would have chosen for the patient with metastatic endometrial cancer in the presented case.
Robert Holloway, MD, review safety and efficacy data from a clinical trial investigation of lenvatinib combined with pembrolizumab for the treatment of advanced endometrial cancer.
An expert details the currently available systemic therapies for patients with MMR-proficient metastatic endometrial cancer who experienced recurrent disease after platinum-based chemotherapy.
Dr Robert Holloway describes the presentation of a typical patient with metastatic endometrial cancer, and whether all patients receive MMR testing.